Life Sciences Group

SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing oncology therapies, with a primary focus on hematologic malignancies and selected solid tumors. Its lead program is galinpepimut-S, a WT1-targeting peptide immunotherapy being evaluated in the pivotal Phase 3 REGAL study for acute myeloid leukemia in second complete remission. The company is also advancing SLS009 (tambiciclib), a selective CDK9 inhibitor, in AML and other hematologic cancers, including combination studies with venetoclax and azacitidine and additional development activities through partner GenFleet in China. SELLAS has positioned itself as an oncology-focused developer rather than a diversified platform company, with assets sourced through licensing and collaboration agreements including Memorial Sloan Kettering Cancer Center and Merck. The company is publicly traded on Nasdaq and headquartered in New York.